Company news: Eli Lilly

Share this article:
Eli Lilly said its Phase III AWARD trials for its weekly dulaglutide GLP-1 drug, in testing for type 2 diabetes,  met primary efficacy endpoints and demonstrated superiority for HbA1c lowering over exenatide and metformin. The most frequently reported adverse events were gastrointestinal-related and consistent with prior studies, said the company. A number of additional studies are ongoing as part of the AWARD battery.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.